Pharmaceutical Assets Portal project Scientists know there are drugs that have been developed, tested and found lacking for one disease that might help patients with a completely different condition. But the trick for researchers has always been finding out about them. While the National Institutes of Health and the pharmaceutical industry maintain portfolios of investigational and FDA-approved … Read More
News
Biovista sponsors EACL-09 Conference
Biovista announced today its sponsoring of the 12th Conference of the European Chapter of the Association for Computational Linguistics (EACL-09) to be held in Athens, Greece, 30 March – 3 April 2009. The conference covers a broad spectrum of disciplines working towards enabling intelligent systems to interact with humans using natural language, and towards enhancing human-human … Read More
Biovista Nutrition application released for the Apple iPhone
Charlottesville, January 28, 2009 Biovista announced today the availability of its Biovista Nutrition application for the Apple iPhone. Biovista Nutrition for the iPhone (BNi) provides information on the interaction of nutritional supplements with drugs and diseases. “We are pleased to have launched this mobile application that can provide useful first level information to consumers at … Read More
Biovista to present at drug repurposing conferences
Charlottesville, VA, 3 November, 2008 Biovista is glad to announce its sponsoring of the Drug Repurposing Strategies conference to be held in Philadelphia, December 10-11, 2008. Focusing on the identification, licensing and repositioning of compounds and existing or abandoned drugs, the conference will explore strategies and approaches to bolster pipelines, reduce risk and control the … Read More
Cempra Pharmaceuticals and Biovista Inc. enter agreement for macrolide CT design support
CHAPEL HILL, N.C. and CHARLOTTESVILLE, Va.–(Business Wire)–Cempra Pharmaceuticals, Inc., and Biovista, Inc., announced today that they have entered into a research agreement to systematically identify and profile adverse event associations for members of the macrolide drug class. The data generated will be used to better understand the unique benefit/risk characteristics of this important group of … Read More